Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) President Cam Gallagher sold 1,173 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $13,419.12. Following the transaction, the president now directly owns 643,277 shares in the company, valued at $7,359,088.88. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Zentalis Pharmaceuticals Stock Performance
Shares of ZNTL stock opened at $11.50 on Tuesday. The firm has a 50-day moving average of $13.65 and a 200-day moving average of $17.62. Zentalis Pharmaceuticals, Inc. has a one year low of $9.56 and a one year high of $31.46.
Institutional Investors Weigh In On Zentalis Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE boosted its stake in shares of Zentalis Pharmaceuticals by 88.7% in the 2nd quarter. US Bancorp DE now owns 887 shares of the company’s stock worth $25,000 after buying an additional 417 shares during the last quarter. Captrust Financial Advisors increased its position in shares of Zentalis Pharmaceuticals by 15,160.0% during the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after acquiring an additional 758 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Zentalis Pharmaceuticals by 132.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock worth $36,000 after acquiring an additional 1,030 shares during the period. Quest Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter worth $38,000. Finally, Point72 Hong Kong Ltd bought a new position in Zentalis Pharmaceuticals in the 1st quarter valued at $72,000.
Wall Street Analyst Weigh In
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
- Five stocks we like better than Zentalis Pharmaceuticals
- Industrial Products Stocks Investing
- 3 attractive stocks that insiders are buying
- How to Invest in Toy Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What Does Downgrade Mean in Investing?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.